Sign inJoin waitlistJoin the waitlist

Sekwon Jang

Siewick Director, Cancer Research · Inova Schar Cancer Institute

Credentials: · · · · · ·

History

Cancer Research · Inova Schar Cancer Institute
Present
Melanoma and Cutaneous Oncology Therapeutics and Research · Inova Schar Cancer Institute
Present
Inova Schar Cancer Institute
Present

Hematology and Medical Oncology
University of Minnesota
2007–2010
Internal Medicine
Jefferson Health Medical Education
2004–2007
Albert Einstein Medical Center
2001–2004
Seoul National University College of Medicine
1997–2001

Research

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label,…
The Lancet Oncology · 2021 · 288 citations
Which drug, and when, for patients with BRAF-mutant melanoma?
Review · The Lancet Oncology · 2013 · First of 2 authors · 152 citations
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given…
Journal of Clinical Oncology · 2023 · 118 citations

Suraj Venna
7 papers
Jennifer DeSimone
6 papers
Michael Atkins
6 papers
Jafar Al-Mondhiry
4 papers
KL
Karl Lewis
4 papers
Hussein Tawbi
3 papers
Igor Puzanov
3 papers
John Glaspy
3 papers
NM
Navneet Majhail
3 papers
NK
Nikhil Khushalani
3 papers
Omid Hamid
3 papers
ST
Sach Thakker
3 papers

Clinical trials

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
Principal investigator · Withdrawn · Phase 2
Inova Health Care Services
2017–2018
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027